A MAJOR BREAKTHROUGH IN CANCER TREATMENT USING NOVEL ZINC TRANSPORTER ANTIBODIES

Zinc is essential for the normal growth of all healthy cells. Furthermore, zinc has been known to be essential for the process of cell division for over 50 years but until our recent discovery the mechanism was completely unknown.

Over the last 20 years we have worked to decipher the exact mechanism of action of zinc transporters and this has led to the discovery of how two specific zinc transporters are needed to cause cell division. This is a very important discovery which can now be exploited to generate agents capable of preventing cell division and be used as treatments for diseases such as cancer.

Our new agents (AMS-1, AMS-2, AMS-3) have been used successfully in the laboratory to prevent the growth of multiple cancer types, including, triple negative breast cancer, anti-hormone resistant breast cancer, colon cancer, prostate cancer and melanoma.

Additionally, our best agent, AMS-3, has produced remarkable results in triple negative breast cancer xenografts. AMS-3 not only prevents tumour growth (97%) it also destructs the original tumour with 40% tumours being completely destroyed. Interestingly, these zinc transporters also act to prevent the cancer cells detaching from tumours and spreading around the body, a positive additional effect.

All this data was achieved with no side effects in animals, equivalent to 10 years in humans. This included confirmation of no effect on the immune system and no change in gut cell performance. This exciting result may in part be due to the extremely low dose required for AMS-3 of 0.1mg/Kg.

This amazing new discovery provides a breakthrough opportunity to become part of a new ‘first in human’ cancer therapy. We are hoping that major investors at this stage will be able to maintain first rights going forward, allowing exclusion of potential competitors.

Contact Kathryn Taylor

email: [email protected]

Tel: +44 2920 875292